Disproportionality analysis of upadacitinib-related adverse events in inflammatory bowel disease using the FDA adverse event reporting system

BackgroundUpadacitinib, a Janus kinase inhibitor, has been increasingly used over the past few years to treat moderate to severe ulcerative colitis and Crohn’s disease in patients who are insufficiently responsive or intolerant to tumor necrosis factor (TNF) antibodies, demonstrating notable clinica...

Full description

Bibliographic Details

Published in:	Frontiers in Pharmacology
Main Authors:	Shiyi Wang, Xiaojian Wang, Jing Ding, Xudong Zhang, Hongmei Zhu, Yihong Fan, Changbo Sun
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-02-01
Subjects:	upadacitinib adverse event FAERS pharmacovigilance data mining
Online Access:	https://www.frontiersin.org/articles/10.3389/fphar.2025.1436183/full